Preclinical testing of RRx-001 in mouse models of experimental endometriosis reveals promising therapeutic impacts

Iona McIntyre, V. B. Vasilyev, Chiara Lia Perrone, C. Perrone, Priya Dhami, Kavita Panir, Matthew Rosser, Erin Greaves
In: bioRxiv · 2024 · doi:10.1101/2024.08.12.607591 · W4401504561
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

In mouse models, RRx-001 demonstrated therapeutic impacts on experimental endometriosis by inducing lesion regression and attenuating pain through macrophage modulation without affecting fertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a chronic inflammatory condition characterised by the presence of ectopic endometrial-like tissue (lesions), reduced fertility and chronic pain. Impacting both the health and psycho-social functioning of millions of women worldwide, there is an urgent need for innovative non-hormonal, non-invasive treatments for the disorder. Both peritoneal and lesion-resident macrophages have been strongly implicated in the pathogenesis of endometriosis; key roles include promotion of lesion growth, neuroangiogenesis and nerve sensitization. With such a central role in the disease, macrophages represent a novel therapeutic target. In the current preclinical study, we sought to repurpose the macrophage targeting anti-cancer drug RRx-001 for the treatment of endometriosis. We utilised mouse models of induced endometriosis to demonstrate that RRx-001 induces regression of endometriosis lesions and attenuates pain-like behaviours, without negatively impacting fertility. Targeted depletion of peritoneal cavity macrophages significantly impairs lesion reduction, demonstrating their critical role in mediating the anti-endometriosis impact of RRx-001. Using single nuclei multiomics, we identified a modification of macrophage subpopulations in the peritoneal cavity, specifically reduced acquisition of a pro-disease phenotype and an accumulation of a pro-resolving phenotype. These observations signify the potential of RRx-001 as a novel therapeutic for endometriosis management.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (75)

Source provenance

europepmc
last seen: 2026-06-04T01:45:00.660873+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK